Market capitalization | $390.00k |
Enterprise Value | $134.51m |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.09 |
P/S ratio (TTM) P/S ratio | 0.01 |
Revenue growth (TTM) Revenue growth | 16.89% |
Revenue (TTM) Revenue | $64.27m |
EBIT (operating result TTM) EBIT | $-355.52m |
Free Cash Flow (TTM) Free Cash Flow | $-243.21m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Sorrento Therapeutics, Inc. forecast:
2 Analysts have issued a Sorrento Therapeutics, Inc. forecast:
Jun '23 |
+/-
%
|
||
Revenue | 64 64 |
17%
17%
|
|
Gross Profit | 24 24 |
22%
22%
|
|
EBITDA | -336 -336 |
8%
8%
|
EBIT (Operating Income) EBIT | -356 -356 |
7%
7%
|
Net Profit | -548 -548 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Henry Ji |
Founded | 1989 |
Website | sorrentotherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.